Handelsavisen
prelaunch
Companies ›Healthcare ›1789.TW
17
1789.TW — TWSE Pharmaceuticals

ScinoPharm Taiwan Ltd

$19,05
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
1,72 %
Op margin
3,5 %
ROE
1,3 %
Net margin
4,3 %
Debt / equity
0,07
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

ScinoPharm Taiwan Ltd is a pharmaceutical company that develops and commercializes generic and branded drugs, primarily in the Asia-Pacific region.

Business. ScinoPharm Taiwan Ltd (1789.TW) is a pharmaceutical company headquartered in Taiwan that operates within the Healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Taiwan Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
1 buy1 hold0 sell
Avg 12m price target26,50

Analyst recommendations

2 analysts · consensus Buy
Buy1
Hold1
Sell0
12-month price target
26,50
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership
—
not yet wired
Profitability→
1,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1789.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1789.TW. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ScinoPharm Taiwan Ltd (1789.TW) is a pharmaceutical company headquartered in Taiwan that operates within the Healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Taiwan Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    ScinoPharm maintains a strong liquidity position, with a current ratio of 7.74 and cash and equivalents amounting to TWD 2,993.5 million, which is significantly higher than the typical liquidity requirements for a company of its size. The company's debt-to-equity ratio is 0.07, indicating a conservative capital structure with minimal reliance on debt financing.

    The company's profitability metrics are modest, with a return on equity (ROE) of 1.3% and a return on assets (ROA) of 1.15%. These figures are below the industry median for pharmaceutical companies, suggesting that ScinoPharm is not generating returns at a level that is typical for its sector. The operating margin, calculated as operating income of TWD 111.16 million on revenue of TWD 3.16 billion, is also relatively low, indicating that the company is facing cost pressures or is operating in a highly competitive market.

    ScinoPharm's revenue is primarily concentrated in the Asia-Pacific region, with a significant portion derived from its domestic market in Taiwan. The company does not disclose detailed segment data, but its exposure to a single geographic region could pose a risk if regulatory or economic conditions in the region deteriorate.

    The company's growth trajectory appears to be modest, with no significant revenue growth reported in the latest financial period. The outlook for the current fiscal year is neutral, with no substantial changes expected in the near term. The company's capital expenditure of TWD -291.29 million suggests that it is not investing heavily in new projects or expansion, which could limit its long-term growth potential.

    Risk factors for ScinoPharm include the potential for regulatory changes in the pharmaceutical industry, which could impact its product approvals and market access. The company also faces competition from both global and regional players, which could pressure its pricing and market share. However, the risk assessment indicates that there are no immediate liquidity or dilution concerns, with a low risk rating for both.

    Recent events, including analyst estimates, suggest a neutral outlook for the company. The mean price target of TWD 26.50 is consistent across all estimates, with no strong buy recommendations issued. This suggests that analysts do not expect significant upside in the near term, but also do not anticipate a decline in the company's stock price.

    Key takeaways
    • ScinoPharm has a strong liquidity position with a current ratio of 7.74 and significant cash reserves.
    • The company's profitability metrics are below industry medians, indicating room for improvement in operational efficiency.
    • Revenue is concentrated in the Asia-Pacific region, which could expose the company to regional economic or regulatory risks.
    • Analysts have a neutral outlook for the company, with a mean price target of TWD 26.50 and no strong buy recommendations.
    • The company is not currently facing immediate liquidity or dilution risks, but its modest capital expenditures may limit long-term growth.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $19,05
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $10.52B
    Net cashⓘ
    $2.23B
    Current ratioⓘ
    7.7
    Debt / equityⓘ
    0.1
    ROAⓘ
    1.1%
    ROEⓘ
    1.3%
    Cash conversionⓘ
    435.0%
    CapEx / revenueⓘ
    -9.2%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,53
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-20 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,53
    Revenue—no estimate—no estimate3,6B TWD
    Operating income—no estimate—no estimate449,5M TWD
    Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy1
    Hold1
    Sell0
    Strong sell0
    12-month price target$26,50 · Median $26,50
    Low $26,50High $26,50
    Operating income · consensus449,5M TWD
    EPS surprise
    −67,6 %
    reported vs consensus · miss
    Revenue surprise
    −12,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$26,50
    Mean$26,50
    Median$26,50
    High$26,50
    Spot$19,05
    +39.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin3,5 %Below median
    Net Margin4,3 %Above median
    ROE1,3 %Below median
    Capex / Rev-9,2 %Below median
    D/E0,07Above median
    Cash Conv4,35Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ScinoPharm Taiwan Ltd Market data — financials · 2026-05-26
    • ScinoPharm Taiwan Ltd Market data — analyst estimates · 2026-05-26
    • ScinoPharm Taiwan Ltd Market data — ESG · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1789.TWCanonical
    TWSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage